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The aberrant accumulation of lipids in the liver (‘‘fatty
liver’’) is tightly associated with several components
of themetabolic syndrome, including type 2diabetes,
coronary heart disease, and atherosclerosis. Herewe
show that the impaired hepatic expression of tran-
scriptional cofactor transducin beta-like (TBL) 1
represents a common feature of mono- and multi-
genic fatty liver mouse models. Indeed, the liver-
specific ablation of TBL1 gene expression in healthy
mice promoted hypertriglyceridemia and hepatic
steatosis under both normal and high-fat dietary
conditions. TBL1 deficiency resulted in inhibition of
fatty acid oxidation due to impaired functional coop-
eration with its heterodimerization partner TBL-
related (TBLR) 1and thenuclear receptor peroxisome
proliferator-activated receptor (PPAR) a. As TBL1
expression levels were found to also inversely corre-
latewith liver fat content in humanpatients, the lackof
hepatic TBL1/TBLR1 cofactor activity may represent
amolecular rationale for hepatic steatosis in subjects
with obesity and the metabolic syndrome.
INTRODUCTION
Triglycerides (TGs) represent the most efficient form of energy
storage in mammals. While storage of TGs in adipose tissue isCessential for the maintenance of normal energy homeostasis,
aberrant lipid accumulation in peripheral tissues, such as liver,
pancreas, and skeletal muscle, is considered to be a key feature
of severe metabolic disorders (Saltiel, 2001).
In humans, the aberrant accumulation of lipids in the liver
(nonalcoholic fatty liver disease, NAFLD) has been reported in
15%–80% of normal and obese individuals, respectively (Ruhl
and Everhart, 2004). As a hallmark of the metabolic syndrome,
fatty liver conditions are tightly associated with insulin resistance
and type 2 diabetes (Seppala-Lindroos et al., 2002) and can
trigger a progressive cascade of lipid disorders, ranging from
hepatic steatosis to nonalcoholic steatohepatitis (NASH),
chronic liver disease, and eventually hepatocellular carcinoma
(Park et al., 2010). Furthermore, fatty liver disease has recently
been characterized as an independent risk factor for coronary
heart disease and atherosclerosis in Western societies (Fabbrini
et al., 2009; Gastaldelli et al., 2009).
However, while fatty liver has been connected with numerous
impairments of energy homeostasis, the molecular determinants
of fatty liver development remain largely unknown.
By wiring distinct transcriptional networks through gene-
specific interactions with DNA-binding transcription factors,
transcriptional cofactor complexes have been identified as crit-
ical checkpoints in the coordination of metabolic programs
(Spiegelman and Heinrich, 2004), exemplified by nuclear
receptor cofactors peroxisome proliferator-activated receptor
coactivator (PGC) 1, receptor-interacting protein (RIP) 140, or
the steroid hormone receptor coactivators (SRCs) and their roles
in the development of hyperglycemia, hepatic steatosis, and
hypertriglyceridemia (Berriel Diaz et al., 2008; Feige and Auwerx,
2007; Herzig et al., 2001; Yoon et al., 2001). In this respect,ell Metabolism 13, 389–400, April 6, 2011 ª2011 Elsevier Inc. 389
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Figure 1. Hepatic Expression of TBL1 Is
Reduced in Fatty Livers
(A) mRNA levels of indicated transcriptional
cofactors in livers of obese NZO and wild-type
NZB mice under random fed conditions (nR 4).
(B) Western blot of liver extracts from four repre-
sentative NZO and NZB mice using TBL1 or VCP
antibodies.
(C) TBL1 mRNA levels in livers of wild-type
or obese db/db mice and wild-type mice fed
a high-fat (HFD) or control diet (LFD, 60% and
10% calories from fat, respectively) for 16 weeks
(nR 6).
(D) TBL1 mRNA levels in primary mouse hepato-
cytes treated with 100 mM palmitate or 5% intra-
lipid for 24 hr (nR 6).
(E) TBL1 mRNA levels in livers of wild-type mice
injected with 100 ml intralipid emulsion (n = 6)
(means ± SEM). * indicates significance.
(F) Pearson correlation coefficient and P value
shown for normalized TBL1 mRNA levels versus
TG content in liver samples from human donors
(n = 37). See also Figures S1 and S7.
Cell Metabolism
TBL1 Controls Hepatic Steatosisparticularly the differential gene expression of specific transcrip-
tional regulators between healthy and metabolic disease
conditions has been found to often reflect a causal, functional
role of these factors in the pathogenesis of type 2 diabetes,
cancer cachexia, and obesity, respectively (Berriel Diaz et al.,
2008; Herzig et al., 2001; Yoon et al., 2001).
Consequently, we hypothesized that the dysregulation of
distinct transcriptional cofactor gene expression under fatty liver
conditions directly mirrors alterations of hepatic lipid homeo-
stasis and may causally contribute to the fatty liver phenotype.
In this study, we identify the inhibition of transcriptional
cofactor TBL1 gene expression as a conserved and functionally
important checkpoint in the manifestation of hepatic steatosis.
Originally cloned in relationship to an X-linked human disorder,
ocular albinism with late-onset sensorineural deafness (OASD)
(Bassi et al., 1999), TBL1 was subsequently identified as
a component of a silencing mediator of retinoid and thyroid
receptors (SMRT)/nuclear receptor corepressor (NCoR)/histone
deacetylase (HDAC) 3 containing cofactor complex (Guenther
et al., 2000; Yoon et al., 2005), involved in both gene repression
and activation via distinct subsets of nuclear receptors (Perissi390 Cell Metabolism 13, 389–400, April 6, 2011 ª2011 Elsevier Inc.et al., 2004). The biological, and in partic-
ular, tissue-specific functions of TBL1 in
the adult organism, however, remained
unknown.
RESULTS
Hepatic TBL1 Expression Is
Impaired in Fatty Liver Mouse
Models and Negatively Correlates
with Hepatic TG Content in Humans
In order to identify transcriptional cofac-
tors involved in (dysfunctional) hepatic
lipid homeostasis in obesity and/or
the metabolic syndrome, we selectivelyinvestigated cofactors exemplifying nuclear receptor, inflamma-
tory, and hormonal (cAMP) signaling in liver. In this context, we
screened for differential cofactor expression in livers of New
Zealand obese (NZO) and lean wild-type New Zealand black
(NZB) mice, the former representing a multigenic model of
obesity-related fatty liver disease and type 2 diabetes (Leiter
and Reifsnyder, 2004). mRNA expression levels of p160
cofactors SRC1 and -2, RIP140, CREB-binding protein (CBP),
and P300 remained unchanged between NZO and NZB mice
under ad libitum fed conditions (Figure 1A). In contrast, hepatic
mRNA, as well as protein expression of transcriptional cofactor
TBL1, was significantly repressed in NZO mice (Figures 1A and
1B). To test whether the hepatic inhibition of TBL1 represents
a more common feature of obesity-related dyslipidemia, we
studied db/db as well as high-fat-diet-fed mice as independent
standard models for monogenic and nutrition-induced obesity
and type 2 diabetes, respectively (Clee and Attie, 2007; Stienstra
et al., 2007). Indeed, TBL1 mRNA and protein levels were
found to be reduced in livers of both obesity models as
compared with controls (Figure 1C, see Figures S1A and S1B,
available online).
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Figure 2. Liver-Specific TBL1 Deficiency
Promotes Hepatic Steatosis
(A) Western blot of liver, abdominal WAT, and
gastrocnemius muscle (SkM) extracts from fed
representative TBL1 (lanes 1–3) or control (lanes 4–
6) shRNA adenovirus-injected C57Bl6 mice 7 days
after injection using TBL1 and VCP antibodies.
(B–D) Liver (B), lipoprotein-associated serum TG
(C), and total serum ketone body (D) levels in the
same mice as in (A) (nR 7) (means ± SEM). * indi-
cates significance. See also Figure S2.
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TBL1 Controls Hepatic SteatosisTo identify potential triggers of TBL1 gene inhibition under
obesity-related conditions, we next monitored TBL1 mRNA
levels in response to hormonal stimulation of isolated primary
mouse hepatocytes. Neither insulin, cAMP agonist forskolin,
nor a glucocorticoid analog affected TBL1 mRNA expression in
these cells (data not shown). However, exposure of primary
hepatocytes to either palmitate or intralipid emulsion signifi-
cantly inhibited TBL1mRNA levels (Figure 1D), showing that fatty
acids can impair TBL1 expression in a cell-autonomous manner.
Consistent with a fatty acid-sensitive control of TBL1 gene
expression, intragastric infusion of a lipid emulsion into wild-
type mice also led to a reduction of hepatic TBL1 mRNA and
protein expression after 6 hr (Figure 1E, Figure S1C).
Importantly, reduced TBL1 mRNA levels significantly corre-
lated with increased liver TG content in a human patient cohort
(Figure 1F, Figures S1D and S7), further substantiating the notion
that the impairment of TBL1 expression highlights an unantici-
pated and conserved feature of steatotic liver metabolism in
mice and humans.
Liver-Specific TBL1 Deficiency Promotes Hepatic
Steatosis and Hypertriglyceridemia
To address the liver-specific function of TBL1, we disrupted the
activity of TBL1 in livers of lean wild-type mice by delivering an
adenovirus expressing TBL1-specific or nonspecific control
shRNA via tail vein injection. TBL1 shRNA treatment significantly
reduced hepatic TBL1 mRNA and protein levels as compared
with control shRNA-injected littermates under both fasting and
fed conditions (Figure 2A, Figures S2A and S2B), while TBL1
expression in abdominal white adipose tissue (WAT) and skeletal
muscle (SkM) remained unaffected (Figure 2A). At day 7 after
injection, acute knockdown of TBL1 caused nomajor differences
in serum cholesterol levels (Figure S2C), blood glucose and fedCell Metabolism 13, 389–serum insulin levels (Figures S2D and
S2E), circulating nonesterified fatty acids
(FFAs) (Figure S2F), body weight (Fig-
ure S2G), total body fat content (Fig-
ure S2H), and markers of liver damage
(Figure S2I) compared with controls.
In contrast, loss of hepatic TBL1 resulted
in a significant increase in fasting liver
cholesterol levels (Figure S2C) and partic-
ularly in hepatic and very-low-density-
lipoprotein (VLDL)-associated serum TG
levels in the fed and fasted states (Figures
2B and 2C, Figure S2K), while cholesterollevels in the fed liver and lipoprotein-associated serum
cholesterol levels remained unaffected (Figures S2J and S2L),
indicating that TBL1 predominantly prevents hepatic TG accu-
mulation in wild-type animals. Further supporting these mouse
data, hepatic TBL1 mRNA levels also negatively correlated
with serum TG levels in humans (Figure S2M).
Liver TG stores are determined by the relative balance of lipid
uptake and release, de novo TG formation (lipogenesis), and
fatty acid combustion via b-oxidation (Postic and Girard, 2008).
To determine whether changes in the fatty acid oxidation
pathway contribute to the observed phenotype, we measured
the circulating levels of total ketone bodies in control and
TBL1-depleted animals. Consistent with higher hepatic TG
content, mice deficient in hepatic TBL1 showed decreased
levels of ketone bodies in the serum (Figure 2D), indicating
reduced hepatic oxidation of fatty acids. In congruence,
genomic expression profiling revealed particularly decreased
expression of genes in the mitochondrial and peroxisomal fatty
acid oxidation pathways (Figure S2N), indicating that disruption
of TBL1 expression promotes steatosis by specifically blunting
hepatic fatty acid combustion. Indeed, hepatic VLDL release re-
mained unaffected upon hepatic TBL1 deficiency (Figure S2O).
To confirm the results from acute knockdown experiments
(Figures 2A–2D) in an independent setting, wild-type mice were
injected with an adeno-associated virus (AAV) expressing
a TBL1-specific miRNA or a nonspecific control miRNA under
the control of a hepatocyte-specific promoter, allowing the
expression of inhibitory miRNAs specifically in liver parenchymal
cells but not in other liver cell types for a period of several months
(Figure S3A; data not shown). After 12 weeks, TBL1 miRNA
delivery led to a more than 50% decrease in hepatic TBL1
mRNA levels (Figure S3B) and almost completely abolished
TBL1 protein expression in liver as compared with control400, April 6, 2011 ª2011 Elsevier Inc. 391
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Figure 3. Long-Term Hepatic TBL1 Defi-
ciency Aggravates Liver Lipid Accumulation
under High-Fat Diet Conditions
(A) Western blot of liver extracts from representa-
tive TBL1 (lanes 1–3) or control (lanes 4–6) miRNA
AAV-injected C57Bl6mice 3months after injection
using TBL1 and VCP antibodies. Mice were kept
on a high-fat (HFD) diet (60% calories from fat) for
12 weeks (nR 8).
(B–D) Total serum ketone body (B), liver TG (C)
levels, and TG content of serum fractions by FPLC
(D) in the samemice as in (A) (nR 8). Animals were
analyzed in the fasted state.
(E) Liver TG levels after injection of TBL1 over-
expression virus in db/db animals (n = 7) for 7 days
under fed conditions.
(F) Palmitate oxidation determined in liver explants
from the same mice as in (E) (n = 21).
(G) mRNA levels of fatty acid oxidation genes
in livers of the same mice as in (E) (n = 7)
(means ± SEM). * indicates significance. See also
Figure S3.
Cell Metabolism
TBL1 Controls Hepatic SteatosismiRNA- or PBS-injected littermates (Figure S3C and data not
shown). Long-term inactivation of TBL1 triggered hepatic TG
accumulation (Figure S3D) and an increase in VLDL-associated
TG (Figure S3E), while leaving liver (Figure S3F) and serum
cholesterol (Figure S3E) as well as blood glucose levels unaf-
fected (Figure S3G). Furthermore, AAV delivery caused no
obvious signs of liver damage or hepatic inflammation as deter-
mined by unchanged alanine aminotransferase (ALT) serum
levels and liver cytokine expression, respectively, when
compared with PBS-injected controls (Figure S3P and data not
shown).
Chronic excess of caloric intake is the major prerequisite for
the worldwide increase in obesity prevalence (Shoelson et al.,
2007), prompting us to next explore the effects of hepatic
TBL1 deficiency on energy metabolism under long-term high-
fat dietary conditions. To this end, AAV miRNA-injected mice
were placed on a high-fat (60% calories from fat) diet for392 Cell Metabolism 13, 389–400, April 6, 2011 ª2011 Elsevier Inc.12 weeks. Consistent with results from
acute and chronic TBL1 loss-of-function
data under chow-fed conditions (Figures
2A–2D, Figures S3B–S3G) and corre-
lating with significantly decreased serum
ketone body levels (Figure 3B), hepatic
TBL1 deficiency (Figure 3A, Figure S3H)
triggered a significant increase in hepatic
TG and serumVLDL TG levels under high-
fat diet feeding (Figures 3C and 3D), but
left other metabolic parameters generally
unaffected (Figures S3I–S3L). These data
further underlined the notion that hepatic
TBL1 is required for the protection
against hypertriglyceridemia and hepatic
TG overload, and that TBL1 deficiency
aggravates fatty liver development and
hypertriglyceridemia even under condi-
tions of chronic energy surplus. Indeed,
overexpression of TBL1 in livers of stea-totic db/db mice (Figure S3M) was sufficient to reduce liver TG
levels (Figure 3E, Figure S3N) and to induce hepatic fatty acid
oxidation and expression of peroxisomal as well as mitochon-
drial fatty acid oxidation enzyme genes in these animals (Figures
3F and 3G), while showing no effect on circulating total serum TG
levels under these conditions (Figure S3O).
Hepatic TBL1 Acts in Concert with TBLR1 to Regulate
Liver Lipid Metabolism
We next sought to explore the mechanistic basis for TBL1 func-
tion in lipid homeostasis. Therefore, we acutely disrupted the
activity of its highly related heterodimerization partner TBLR1
(Guenther et al., 2000; Yoon et al., 2005) by adenoviral delivery
of a TBLR1-specific shRNA into fasted or fed wild-type mice.
Noteworthily, in contrast to TBL1, TBLR1 mRNA levels remained
unchanged under steatotic conditions in animal models or upon
lipid exposure of primary hepatocytes (Figure S1A–S1C).
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Figure 4. Knockdown of Hepatic TBLR1
Phenocopies Liver TBL1 Deficiency
(A and B) Liver TG (A) and total serum ketone body
(B) levels in control or TBLR1 shRNA adenovirus-
injected C57Bl6 mice 7 days after injection under
fed and fasted conditions (nR 7) (means ± SEM). *
indicates significance. See also Figure S4.
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TBL1 Controls Hepatic SteatosisshRNA-mediated loss of hepatic TBLR1 (Figures S4A and
S4B) produced a phenocopy of TBL1 deficiency, as it elevated
liver TG and serum VLDL TG levels by 2- to 3-fold (Figure 4A,
Figures S4C and S4E), reduced circulating ketone body levels
(Figure 4B), and had no major impact on the other metabolic
parameters tested (Figures S4D–S4I). Also, long-term inactiva-
tion of TBLR1 by AAV-mediated miRNA delivery (Figure S4J)
resulted in liver and serum TG accumulation (Figure S4K and
S4L) and decreased ketone body levels (Figure S4M), leaving
liver and serum cholesterol levels as well as blood glucose,
serum insulin, and liver damage marker levels unaffected (Fig-
ure S4L, data not shown).
These results suggested that TBL1 and TBLR1 fulfill similar
roles in hepatic lipid metabolism. Consequently, we performed
double knockdown experiments in wild-type mice by coinjection
of TBL1 andTBLR1 shRNAadenoviruses (Figure 5A, Figure S5A).
In contrast to the 2- to 3-fold elevation of hepatic TG levels upon
single TBL1 or TBLR1 knockdown, respectively, simultaneous
ablation of both TBL1 and TBLR1 resulted in an up to 9-fold
increase in liver TG (Figure 5B, Figures S5B and S5C).
Conversely, combined overexpression of TBL1 and TBLR1 in
primary hepatocytes from steatotic db/db mice significantly
reduced the cellular TG content of these cells (Figure 5C, Fig-
ure S5D), verifying the regulatory function of TBL1/TBLR1 for
hepatic lipid homeostasis in a cell-autonomous manner. In line
with the reduction of ketone body levels upon TBL1/TBLR1
single and double knockdown (Figure 5D), palmitate oxidation
rates in livers from TBL1/TBLR1-deficient animals were dimin-
ished (Figure 5E). Consistently, gene expression profiling re-
vealed that TBL1/TBLR1 knockdown particularly blunted the
expression of genes in the mitochondrial and peroxisomal fatty
acid oxidation pathway and concomitantly led to increased
expression of lipogenic genes as compared to controls (Fig-
ure 5F). Consistent with the reduced expression of hepatic
VLDL/ApoB reuptake transporters (Narvekar et al., 2009; Yen
et al., 2008) (Figure S5E), clearance of human VLDL from serum
(Figure S5F) and lipid clearance after intravenous lipid infusion
(Figure S5G) were both impaired upon hepatic TBL1/TBLR1 defi-
ciency. In congruence, hepatic TBL1/TBLR1 deficiency caused
an almost 3-fold elevation of serum TG levels when compared
to control shRNA- or PBS-injected littermates (Figure S5H).
These results demonstrated that the TBL1/TBLR1 cofactor
complex synergistically exerts a critical regulatory function in
the prevention of hepatic steatosis and hypertriglyceridemia.
Interestingly, hepatic steatosis induced by TBL1/TBLR1 defi-
ciency did not impact intrahepatic insulin signaling strengthC(Figure S5I), but rather mildly improved systemic glucose
clearance and insulin sensitivity in an oral glucose and insulin
tolerance test, respectively (Figure 5G).
TBL1/TBLR1 Cooperate with Nuclear Receptor PPARa
Thus far, our results suggested that the antisteatotic effect of the
hepatic TBL1/TBLR1 cofactor complex predominantly relies on
its activating function for genes involved in fatty acid oxidation
(Figure 5F). The nuclear receptor PPARa has been identified as
a master regulator of fatty acid oxidation in the liver (Kersten
et al., 1999), prompting us to test whether the TBL1/TBLR1
complex might serve as a physiological coactivator for PPARa
in this context. Inhibition of TBL1 expression in primary mouse
hepatocytes reduced the induction of prototypic PPARa target
genes upon treatment of the cells with a PPARa-specific ligand
(Figure 6A), demonstrating that TBL1 is indeed required for full
PPARa transcriptional activity in a cell-autonomous manner. In
agreement, overexpression of TBL1/TBLR1 in primary db/db
hepatocytes activated the expression of PPARa target genes
in the presence and absence of PPARa ligand (Figure 6B), and
single TBL1 overexpression caused the induction of the same
genes in db/db livers in vivo (Figure 6C).
Next, we employed our TBL1/TBLR1 double knockdown
strategy in PPARa knockout mice (Kersten et al., 1999). Consis-
tent with previous reports (Rakhshandehroo et al., 2010), PPAR-
a-deficient animals displayed elevated hepatic and serum TG
levels as well as diminished circulating ketone body levels as
compared with wild-type littermates (Figures 6D and 6E, Figures
S6A and S6B). As shown above, TBL1/TBLR1 double deficiency
produced a similar phenotype as PPARa loss of function in wild-
type mice (Figures 6D and 6E, Figures S6A–S6E), while exerting
no significant effect in PPARa knockout animals in terms of
serum and hepatic TG levels (Figures 6D and 6E) as well as
circulating ketone bodies (Figure S6B). This substantiated
the hypothesis that TBL1/TBLR1 serve as coactivators for
the PPARa transcriptional complex in hepatic lipid homeostasis.
Additional TBL1/TBLR1 loss-of-function experiments in PPARa/
PPARb/d double knockout mice (Bedu et al., 2007) produced
identical results to the PPARa single knockout model (Fig-
ure S6F), underlining the specific importance of the PPARa
isoform for TBL1/TBLR1 action in this context.
To verify the functional connection between TBL1/TBLR1 and
PPARa independently, we performed chromatin immunoprecip-
itation assays using liver extracts from wild-type and PPARa
knockout mice. Remarkably, prototypic PPARa target gene
promoters (cytochrome P450 [CYP] 4A10 and CYP4A14) wereell Metabolism 13, 389–400, April 6, 2011 ª2011 Elsevier Inc. 393
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Figure 5. TBL1 Controls Hepatic Steatosis in Synergism with TBLR1
(A) Western blot of liver extracts from representative TBL1/TBLR1 (lanes 1–3) or control (lanes 4–6) shRNA adenovirus-injected C57Bl6 mice 7 days after injection
under fed conditions using TBL1, TBLR1, and VCP antibodies.
(B) Liver sections from representative C57Bl6 mice under fed conditions injected with either control, TBL1, TBLR1, or both TBL1/TBLR1 shRNA adenoviruses
7 days after injection stained with oil red O. Lipids stain positive (red color) with oil red O.
(C) TG levels in primary mouse hepatocytes from db/db mice transfected with TBL1 and TBLR1 overexpression plasmids for 48 hr (n = 12).
(D) Total serum ketone body levels in the same mice as in (A) (nR 7).
(E) Palmitate oxidation in liver slices from TBL1/TBLR1 or control shRNA adenovirus-injected C57Bl6 mice (n = 18).
(F) mRNA levels of fatty acid oxidation and lipogenic genes in livers of the same mice as in (A) (nR 7).
(G) Glucose tolerance test (GTT) and insulin tolerance test (ITT) in TBL1/TBLR1 (TT) or control shRNA (NC) adenovirus-injected C57Bl6 mice 7 days after injection
(means ± SEM). * indicates significance. See also Figure S5.
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Figure 6. TBL1/TBLR1 Regulate Liver Lipid
Metabolism via PPARa
(A) mRNA levels of fatty acid oxidation genes in
primary mouse hepatocytes infected with control
or TBL1 shRNA adenovirus (moi = 75). Twenty-four
hours after infection, cells were treated with the
PPARa ligand GW7647 (1 mM) for 24 hr before
harvesting (nR 4).
(B) mRNA levels of fatty acid oxidation genes
in primary db/db hepatocytes infected with control
or TBL1/TBLR1 overexpression adenovirus
(moi = 10). Twenty-four hours after infection, cells
were treated with the PPARa ligand GW7647
(1 mM) for 24 hr before harvesting (nR 6).
(C) mRNA levels of fatty acid oxidation genes in
db/db animals injected with control or TBL1
overexpression adenovirus 7 days after injection
(n = 7).
(D and E) Liver (D) and serum (E) TG levels in wild-
type (WT) and PPARa/ mice injected with either
control or TBL1/TBLR1 shRNA adenoviruses
7 days after injection under fed conditions (nR 7).
See also Figure S6. Means ± SEM. * indicates
significance.
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TBL1 Controls Hepatic Steatosisefficiently recovered from liver immunoprecipitates using TBL1
and TBLR1 but not control IgG antibodies in wild-type livers (Fig-
ure 7A). TBL1 and TBLR1 promoter binding was largely reduced
in PPARa knockout mice (Figure 7A), showing that the TBL1/
TBLR1 coactivator complex is directly recruited to metabolic
target gene promoters in a PPARa-sensitive manner in vivo.
Indeed, TBL1 and TBLR1 were found to physically interact with
PPARa in GST pull-down (Figure 7B) as well as in coimmunopre-
cipitation studies of H4IIE hepatocytes (Figure 7C). Furthermore,
abrogation of TBL1 and TBLR1 substantially impaired the
activity of a PPARa-driven reporter gene in Hepa1c1 hepato-
cytes (Figure 7D) and led to an increased recruitment of the
NCoR/HDAC3 corepressor complex to PPARa fatty acid oxida-
tion target genes in livers of mice, accompanied by decreased
histone H4 acetylation at these promoter sites (Figure 6E). In
parallel to the increased recruitment of corepressor complex
components (i.e., HDAC3) to PPARa target promoters, TBL1/
TBLR1 deficiency triggered the release of known PPARa coacti-
vators (i.e., Sirtuin1, Baf60a) from these promoter sites in
cultured Hepa1c1 hepatocytes (Figure 6F), demonstratingCell Metabolism 13, 389–a role for TBL1/TBLR1 in the PPARa core-
pressor/coactivator exchange on fatty
acid oxidation genes in a cell-autono-
mous manner.
DISCUSSION
TBL1 was originally cloned in relationship
to an X-linked human disorder, OASD, in
which deletion of TBL1 was suggested
to be responsible for the hearing defect
(Bassi et al., 1999). Along with the highly
homologous TBLR1 protein, TBL1 was
subsequently identified as a component
of a nuclear receptor SMRT/NCoR/HDAC3 corepressor complex (Guenther et al., 2000; Yoon
et al., 2005).
Our data now provide insights into tissue-specific functions of
the TBL1/TBLR1 cofactor complex with further implications for
the pathogenesis of obesity-related NAFLD. The results of our
studies are consistent with a model in which hyperlipidemic
conditions are correlated with the downregulation of hepatic
TBL1 gene expression, as shown for monogenic (db/db) and
multigenic (NZO and high-fat diet) mouse obesity models, as
well as for human liver samples. An increased exposure of the
liver to lipids/fatty acids might at least in part explain the TBL1
inhibition under these conditions, although other and/or addi-
tional stress signals might also contribute to the control of
TBL1 gene transcription. In any case, TBL1 inhibition is sufficient
to partly block hepatic fatty acid oxidation and to promote liver
TG accumulation, thereby establishing a more permanent inhib-
itory loop for TBL1 gene expression and further aggravating
hepatic steatosis under these conditions.
Intriguingly, the steatosis caused by liver-specific inactivation
of TBL1/TBLR1 did not impair components of the hepatic insulin400, April 6, 2011 ª2011 Elsevier Inc. 395
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Figure 7. TBL1/TBLR1 Regulate Liver Lipid
Metabolism via Direct Interaction with
PPARa
(A) Chromatin immunoprecipitation (ChIP) assay of
liver extracts from fasted wild-type or PPARa/
mice using TBL1, TBLR1, and acetylated histone
H4 (AcH4)-specific antibodies. Precipitated frag-
ments were analyzed by real-time PCR using
promoter primers against CYP4A10 and
CYP4A14. Data show recruitment relative to IgG
and chromatin input (nR 5).
(B) Pull-down assays performed with full-length
TBL1 fused to GST and GST alone as a control.
GST fusion proteins were incubated with in vitro
translated full-length PPARa. Bound proteins were
resolved by SDS-PAGE and visualized by autora-
diography. Input lanes represent 20% of the input.
(C) Coimmunoprecipitation of TBL1, TBLR1, and
PPARa from H4IIE hepatocytes transfected with
Flag-PPARa or an empty vector expressing the
Flag peptide alone using an anti-FlagM2 antibody.
Bound proteins were resolved by SDS-PAGE and
subsequently detected by western blot. IN, input;
SN, supernatant; EL, elution.
(D) Transient transfection assay of Hepa1c1
hepatocytes cotransfected with a 3xPPRE-Luc
reporter plasmid (containing PPAR response
elements) together with plasmids encoding
PPARa, retinoid X receptor (RXR)a, and TBL1/
TBLR1-specific or nonspecific control shRNA
constructs as indicated.
(E) ChIP assay using liver extracts of wild-type
mice injected with either control or TBL1/TBLR1
shRNA adenoviruses as in a using antibodies
specific for NCOR, HDAC3, AcH4, and nonspe-
cific IgG. Precipitated fragments were analyzed by
real-time PCR as in (A). Data show recruitment
relative to IgG and chromatin input (nR 5).
(F) ChIP assay using Hepa1c1 hepatocytes
transfected with Flag-tagged cofactors or an
empty vector expressing the Flag peptide alone,
infected with either control or TBL1/TBLR1 shRNA
adenoviruses using Flag agarose. Precipitated
fragments were analyzed by real-time PCR as in
(A). Data show recruitment relative to Flag peptide
and chromatin input (means ± SEM). * indicates
significance.
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TBL1 Controls Hepatic Steatosissignaling axis but rather led to the improvement of systemic
glucose tolerance and insulin sensitivity. While hepatic steatosis
is tightly associated with insulin resistance in humans and
animals (Angulo and Lindor, 2001; Marchesini et al., 1999), the
causal and potentially mutual links between fatty liver and insulin
resistance remain to be defined. Whereas insulin resistance and
the accompanying hyperinsulinemia have been described to
trigger lipogenesis and liver lipid accumulation via the sterol
regulatory element-binding (SREBP)-1c transcription factor
pathway (Shimomura et al., 1999a, 1999b), studies on the influ-
ence of hepatic lipid accumulation on systemic insulin sensitivity
resulted in ambiguous conclusions: while hepatic overexpres-
sion of lipoprotein lipase or glycerol-3-phosphate acyltransfer-
ase triggers hepatic steatosis and systemic insulin resistance
(Kim et al., 2001; Nagle et al., 2007), transgenic mice overex-
pressing lipogenic acyl-CoA diacylglycerol acyltransferase
genes specifically in the liver are characterized by hepatic lipid396 Cell Metabolism 13, 389–400, April 6, 2011 ª2011 Elsevier Inc.accumulation in the absence of impaired insulin sensitivity or
dysfunctional glucose homeostasis (Monetti et al., 2007), indi-
cating that hepatic steatosis under certain conditions can be
dissociated from the occurrence of insulin resistance and its
adverse effects on glucose metabolism.
Therefore, it is tempting to speculate that the inhibition of TBL1
gene expression in fatty livers and the concomitant impact on
intrahepatic lipid accumulationmay represent a protective rather
than a harmful mechanism for overall systemic energy homeo-
stasis under certain metabolic conditions that await further in-
depth analysis in future studies.
The differential response of TBL1 and TBLR1 gene expression
to fatty acid/lipid exposure and hyperlipidemic conditions
suggests that TBL1 represents the main regulatory site in the
TBL1/TBLR1-dependent lipid gene network. This hypothesis is
indeed supported by both mouse and human data, as hepatic
TBLR1 mRNA levels did not respond to acute and chronic lipid
Cell Metabolism
TBL1 Controls Hepatic Steatosisexposure in animals or cells, nor did they correlate with hepatic
and serum TG levels in human samples. Also, TBL1 gene knock-
down did not impair TBLR1 gene expression directly (data not
shown). However, due to the functional synergism between
TBL1 and TBLR1 in terms of hepatic lipid homeostasis, reduced
TBL1 levelsmay push the stoichiometry of the TBL1/TBLR1 tran-
scriptional complex on lipid metabolizing target genes toward
a functionally less favorable state, thereby determining the over-
all regulatory impact on liver lipid homeostasis and explaining the
functional synergism of the TBL1/TBLR1 complex in this setting.
Indeed, previous studies have shown that TBL1 and TBLR1 are
mutually dependent on each other for their respective recruit-
ment to DNA in specific gene promoter contexts (Li and Wang,
2008). As single TBL1 or TBLR1 gene knockdown also produced
metabolic phenotypes that were not (fully) compensated by the
other binding partner, both TBL1 and TBLR1 may additionally
not only fulfill common but also specific roles in hepatic energy
homeostasis. Future analyses of distinct and overlapping target
gene networks are expected to provide insights into a potential
functional specification within the TBL1/TBLR1 cofactor
complex with respect to liver lipid handling and systemic energy
homeostasis.
Although transcriptional cofactors exert their biological func-
tion by definition through the interaction with various DNA-
binding partners within a given cellular context (Rosenfeld and
Glass, 2001), a large portion of TBL1/TBLR1 effects in hepatic
lipid handling seems to depend on PPARa, suggesting that this
nuclear receptor represents a main mechanistic checkpoint for
TBL1/TBLR1 action in this setting. Indeed, hepatic TBL1/
TBLR1 deficiency produced a phenocopy of the PPARa gene
knockout with respect to liver TG levels, and loss of PPARa
was sufficient to significantly blunt the effects of TBL1/TBLR1
gene knockdown which was not further influenced by the addi-
tional absence of PPARb/d, thereby pointing toward a certain
degree of TBL1/TBLR1 interaction partner preference within
the PPAR transcription factor family. Though part of a core-
pressor complex, TBL1 and TBLR1 seem to also be necessary
for the activation of distinct subsets of nuclear receptors and
other transcription factor families through the recruitment of
the ubiquitin conjugating/19S proteasome complex and the
subsequent degradation of corepressors and attraction of coac-
tivators (Perissi et al., 2004). In agreement with this model,
absence of TBL1/TBLR1 indeed promoted an enrichment of
NCoR and HDAC3 on PPARa target gene promoters involved
in fatty acid oxidation, while triggering the release of known
PPARa coactivators from these sites.
Together, our studies identify the TBL1/TBLR1 transcriptional
coactivator complex as a critical regulatory checkpoint in the
prevention of fatty liver development. Consequently, the loss of
TBL1 expression in fatty livers as documented in both mouse
models as well as human patient samples may represent an
important determinant of susceptibility to NAFLD and obesity-
related dyslipidemia.EXPERIMENTAL PROCEDURES
Recombinant Viruses
Adenoviruses expressing TBL1- or TBLR1-specific or nonspecific shRNA
under control of the U6 promoter or the TBL1 cDNA under control of theCCMV promoter were cloned as described previously (Herzig et al., 2001,
2003). Viruses were purified by the cesium chloride method and dialyzed
against phosphate-buffered-saline buffer containing 10% glycerol prior to
animal injection.
For long-term inactivation of TBL1 and TBLR1, AAVs encoding TBL1 and
TBLR1-specific miRNA under the control of a hepatocyte-specific promoter
were established. For details, please see the Supplemental Information.
Animal Experiments
Male 8- to 12-week-old C57Bl6, db/db, NZO/NZB, and PPARa (/) mice
were obtained fromCharles River Laboratories (Brussels, BEL) andmaintained
on a 12 hr light-dark cycle with regular unrestricted diet. For starvation exper-
iments, animals were fasted for 24 hr or random fed with free access to water.
For adenovirus injections, 13 109 plaque-forming units (pfu) per recombinant
virus were administered via tail vein injection. In each experiment, seven to
eight animals received identical treatments and were analyzed under fasted
or fed conditions as indicated. In high-fat diet experiments, C57Bl6 mice
were injected with 5 3 1011 AAV particles per mouse and fed a high-fat diet
(60% energy from fat, Research Diets D12492) for a period of 12 weeks. In
additional experiments, PPARa (/) and PPARa/b/d (/) double knockout
mice (Bedu et al., 2007) were injected with recombinant adenoviruses as
above.
For intralipid infusions, mice were fasted for 16 hr, and 100 ml of a 20% (v/v)
intra-lipid emulsion in saline (Sigma, Munich, GER) was administered intrave-
nously. Tissue was collected 6 hr after infusion and analyzed by quantitative
PCR as described below. Insulin and glucose tolerance tests were performed
as described previously (Michael et al., 2000).
Organs including liver, epididymal fat pads, and gastrocnemius muscles
were collected after the corresponding time periods, weighed, snap-frozen,
and used for further analysis. Total body fat content was determined by
an Echo MRI body composition analyzer (Echo Medical Systems, Houston,
TX). Animal handling and experimentation was done in accordance
with National Institutes of Health (NIH) guidelines and approved by local
authorities.
Blood Metabolites
Serum levels of glucose, insulin, TGs, cholesterol, total ketone bodies, and
nonesterified fatty acids (NEFAs) were determined using an automatic glucose
monitor (One Touch, Lifescan, Neckargemu¨nd, DEU) or commercial kits (MP
Biomedicals, Orangeburg, NY; Mercodia, Uppsala, SE; Sigma, Munich,
DEU; RANDOX, Crumlin, NIR; WAKO, Neuss, DEU).
Fast Protein Liquid Chromatography
Serum from seven mice per experimental group was pooled and subjected to
fast protein liquid chromatography as previously described (Lichtenstein et al.,
2007). Cholesterol and TG were measured in the eluted fractions using
commercial kits as above.
Hepatic VLDL Release
VLDL production was determined after tyloxapol (Sigma, Munich, DEU)
injection as described (Mandard et al., 2006).
VLDL Clearance
HumanVLDLwas isolated from fasted serum samples by ultracentrifugation as
described (Redgrave et al., 1975). Briefly, 3.5ml serumwas put in a polyallomer
tube SW40Ti andmixed with 1.39 g KBr, overlayered with 33 2.8 ml of a NaCl/
KBr solution (D = 1.063, 1.019, and 1.006 g/ml) and run for 18 hr at 40,000 rpm.
Human VLDL (20 mg) was injected into each animal, and serum samples were
taken at 2, 10, 30, 60, and 120 min. Serum human ApoB-100 levels were
measured using a human-specific ApoB ELISA. For the ELISA, we used
a primary coating antibody generated against human apoB-100 (mAb47,
kindly supplied by J.Witztum,University of SanDiego, USA), in a concentration
of 2 mg/well IgG protein in TBS/EDTA/BHT and a secondary biotinylated
polyclonal antibody raised in goat against human ApoB in a concentration of
4 ug/well in 1.5% BSA/TBS/0.1% Tween. To prevent nonspecific binding,
plates were blocked with 1.5% BSA/TBS/0.1% Tween. Samples were diluted
1:25. Absorbance was read 30min after addition of TMB and termination of the
reaction with 2 M H2SO4 at 450 nm (Groot et al., 1991).ell Metabolism 13, 389–400, April 6, 2011 ª2011 Elsevier Inc. 397
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Hepatic lipids were extracted as described previously (Herzig et al., 2003), and
TG and total cholesterol content was determined using commercial kits as
above. Values were calculated as milligrams (TG and cholesterol) per gram
wet tissue.
Ex Vivo Palmitate Oxidation
Mice were dissected, and three 10–20 mg liver pieces were incubated in
a 48-well plate containing Krebs Ringer buffer with 1% fatty acid free BSA,
5 mM glucose, and 1 mM palmitic acid [3H palmitate, 5mCi/mL] (Perkin Elmer,
Waltham, USA) for 2 hr at 37C and 5% CO2. The reaction was stopped by
adding chloroform/methanol (2:1). Subsequently the aqueous phase was
separated from the organic phase. The aqueous phase was analyzed in
a b-counter. All chemicals if not mentioned otherwise were purchased from
Sigma (Munich, DEU). All measurements were made in triplicates.
Quantitative Taqman RT-PCR
Total RNA was extracted from homogenized mouse liver or cell lysates using
Qiazol reagent (QIAGEN, Hilden, DEU). cDNA was prepared by reverse
transcription using the M-MuLV enzyme and Oligo dT primer (Fermentas,
St. Leon-Rot, DEU). cDNAs were amplified using assay-on-demand kits and
an ABIPRISM 7700 Sequence detector (Applied Biosystems, Darmstadt,
DEU). RNA expression data were normalized to levels of TATA-box binding
protein (TBP) RNA.
Protein Analysis
Protein was extracted from frozen organ samples or cultured hepatocytes
in cell lysis buffer (Rose et al., 2007), and 20 mg of protein was loaded onto
a 8% SDS-polyacrylamide gel and blotted onto nitrocellulose membrane.
Western blot assays were performed as described (Herzig et al., 2001)
using antibodies specific for TBL1 (Abcam, Cambridge, UK), TBLR1 (Novus
Biologicals, Littleton, USA), phospho Ser473 Akt, total Akt (Cell Signaling,
Boston, USA), phospho Ser9 glycogen synthase kinase (GSK) 3, total GSK3
(Upstate, Lake Placid, NY), or valosin-containing protein (VCP) (Abcam,
Cambridge, UK).
Histochemistry and Immunohistochemistry
For hematoxylin and eosin (H&E) and oil red O lipid staining, 5 mmcryosections
of liver embedded in Tissue Tek OCT compound (Sakura, NL) were fixed in
Baker’s formol. Nuclei were counterstained with hematoxylin.
Chromatin Immunoprecipitation Assay
Liver tissue powder samples from fasted (24 hr) wild-type or PPARa (/)
mice; from wild-type animals injected with control or TBL1/TBLR1 adenovirus;
or from cellular lysates of Hepa1c1 cells transfected with Flag-tagged Sirtuin1,
Baf60a, or HDAC3 were fixed with formaldehyde in PBS, and ChIP assays
were performed as described (Canettieri et al., 2003) using antibodies specific
for acetylated histone H4 (Upstate, Lake Placid, NY), TBL1, TBLR1, NCOR,
HDAC3, unspecific IgG (Santa Cruz, Heidelberg, DEU), or Flag agarose
(Sigma, Munich, DEU). Precipitated DNA fragments were analyzed by PCR
amplification using primers directed against the murine cytochrome P450
(CYP), 4A10, and CYP4A14 gene promoters (SABiosciences, MD, USA).
Coimmunoprecipitation
H4IIE hepatocytes were cotransfected with a Flag-PPARa or an empty Flag
vector. Subsequently, cells were lysed, centrifuged, and the supernatant
incubated with anti-FlagM2Agarose (Sigma,Munich, DEU) for 2 hr. The immu-
noprecipitates were subsequently analyzed by western blot as described.
GST Pull-Down
GST fusion proteins (pGEX5.1, pGEX5.1-GST_TBL1) were produced in BL21
cells and affinity purified using glutathione Sepharose (Amersham Biosci-
ences, Darmstadt, DEU). In vitro transcription/translation was performed using
the TNT T7/T3 quick coupled transcription/translation system (Promega, Man-
nheim, DEU) according to the manufacturer’s instructions. GST and in vitro
translated proteins were incubated at 4C overnight. After extensive washing,
GST-precipitated proteins were separated by SDS-PAGE and detected by
autoradiography as described (Zschiedrich et al., 2008).398 Cell Metabolism 13, 389–400, April 6, 2011 ª2011 Elsevier Inc.Plasmids and RNA Interference
Oligonucleotides targeting mouse TBL1 (50-GCGAGGATATGGAACCTTAAT-
30) or TBLR1 (50-GCATAAAGGTCCTATATTTGC-30) were annealed and cloned
into the pENTRY RNAi vector (Invitrogen, Karlsruhe, DEU). Nonspecific oligo-
nucleotides (50-GATCTGATCGACACTGTAATG-30) with no significant
homology to any mammalian gene sequence were used as nonsilencing
controls in all experiments. The PPRE-Luc reporter plasmid and expression
vectors for PPARa and retinoid X receptor (RXR) were kindly provided by M.
Downes, La Jolla, CA. Expression vectors for Flag-tagged TBL1 and TBLR1
were generated by standard PCR-based methods and cloned into the
pcDNA3.1 expression vector (Promega, Mannheim, DEU).
Cell Culture and Transient Transfection Assays
Murine Hepa1c1 hepatocytes were transfected using polyethylenimine (PEI)
reagent as described (Reed et al., 2006). Cell extracts were prepared 48 hr
after transfection, and luciferase assays were performed as described (Herzig
et al., 2001), normalizing to the activity from a cotransfected b-galactosidase
expression plasmid. Primary mouse hepatocytes were isolated and cultured
as described (Klingmuller et al., 2006). For further details, please see the
Supplemental Information.
Human Liver Samples
Subjects
Thirty-seven participants were enrolled into a human cross-sectional study
between February 2009 and March 2010. For eligibility, subjects had to
be R18 years old. All patients underwent liver surgery for different medical
reasons and gave their written informed consent at least 24 hr prior to the
study. The experimental protocol was approved by the local ethics committee.
Subjects who underwent chemotherapy prior to surgical intervention, subjects
with a history of liver cirrhosis, who received organ transplantation, or who
suffered from acute or chronic inflammatory diseases were excluded. Long-
term therapy with glucocorticoids or antirheumatic drugs, drug abuse, exces-
sive alcohol consumption, or mental dysfunction was also considered to be
exclusion criteria.
Experimental Design
Upon arrival at the hospital, all volunteers underwent intensive evaluation of
medical history and physical examination. Anthropometric measurements
and arterial blood pressure according to Riva Rocci were obtained. Liver
samples were collected intrasurgically from healthy tissue and were confirmed
to be histologically normal. After resection, liver samples were snapfrozen in
liquid nitrogen within seconds and stored at 80C until further analysis.
Frozen liver tissue was ground in liquid nitrogen to a homogenous powder;
50 mg of tissue was homogenized in 5 ml of 10 mM sodium phosphate buffer
containing 1 mM EDTA and 1% polyoxyethylene 10 tridecylethan, using an
Ultra-Turrax (IKA Werke, Germany). Samples were centrifuged (10 min,
20,0003 g), and the supernatant was incubated at 70C for 5min. TG (SIGMA,
USA) and protein (DC protein assay, Bio-Rad, USA) levels were analyzed in
triplicates.
Statistical Analysis
Statistical analyses were performed using a two-way analysis of variance
(ANOVA) with Bonferroni-adjusted post tests, or t test in one-factorial designs,
respectively. The significance level was p = 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
at doi:10.1016/j.cmet.2011.02.011.
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